174 related articles for article (PubMed ID: 15843513)
1. Cutting edge: in vivo blockade of human IL-2 receptor induces expansion of CD56(bright) regulatory NK cells in patients with active uveitis.
Li Z; Lim WK; Mahesh SP; Liu B; Nussenblatt RB
J Immunol; 2005 May; 174(9):5187-91. PubMed ID: 15843513
[TBL] [Abstract][Full Text] [Related]
2. Regulatory CD56(bright) natural killer cells mediate immunomodulatory effects of IL-2Ralpha-targeted therapy (daclizumab) in multiple sclerosis.
Bielekova B; Catalfamo M; Reichert-Scrivner S; Packer A; Cerna M; Waldmann TA; McFarland H; Henkart PA; Martin R
Proc Natl Acad Sci U S A; 2006 Apr; 103(15):5941-6. PubMed ID: 16585503
[TBL] [Abstract][Full Text] [Related]
3. An IL-2 paradox: blocking CD25 on T cells induces IL-2-driven activation of CD56(bright) NK cells.
Martin JF; Perry JS; Jakhete NR; Wang X; Bielekova B
J Immunol; 2010 Jul; 185(2):1311-20. PubMed ID: 20543101
[TBL] [Abstract][Full Text] [Related]
4. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis.
Sheridan JP; Zhang Y; Riester K; Tang MT; Efros L; Shi J; Harris J; Vexler V; Elkins JS
Mult Scler; 2011 Dec; 17(12):1441-8. PubMed ID: 21807759
[TBL] [Abstract][Full Text] [Related]
5. Unexpected role for granzyme K in CD56bright NK cell-mediated immunoregulation of multiple sclerosis.
Jiang W; Chai NR; Maric D; Bielekova B
J Immunol; 2011 Jul; 187(2):781-90. PubMed ID: 21666061
[TBL] [Abstract][Full Text] [Related]
6. Participation of the CD94 receptor complex in costimulation of human natural killer cells.
Voss SD; Daley J; Ritz J; Robertson MJ
J Immunol; 1998 Feb; 160(4):1618-26. PubMed ID: 9469418
[TBL] [Abstract][Full Text] [Related]
7. An unusual CD56(bright) CD16(low) NK cell subset dominates the early posttransplant period following HLA-matched hematopoietic stem cell transplantation.
Dulphy N; Haas P; Busson M; Belhadj S; Peffault de Latour R; Robin M; Carmagnat M; Loiseau P; Tamouza R; Scieux C; Rabian C; Di Santo JP; Charron D; Janin A; Socié G; Toubert A
J Immunol; 2008 Aug; 181(3):2227-37. PubMed ID: 18641363
[TBL] [Abstract][Full Text] [Related]
8. Population PK-PD analyses of CD25 occupancy, CD56
Diao L; Hang Y; Othman AA; Mehta D; Amaravadi L; Nestorov I; Tran JQ
Br J Clin Pharmacol; 2016 Nov; 82(5):1333-1342. PubMed ID: 27333593
[TBL] [Abstract][Full Text] [Related]
9. Low-dose IL-2 induces CD56
McQuaid SL; Loughran ST; Power PA; Maguire P; Szczygiel A; Johnson PA
Clin Exp Immunol; 2020 Jun; 200(3):228-241. PubMed ID: 31989589
[TBL] [Abstract][Full Text] [Related]
10. Long-term proliferation of functional human NK cells, with conversion of CD56(dim) NK cells to a CD56 (bright) phenotype, induced by carcinoma cells co-expressing 4-1BBL and IL-12.
Dowell AC; Oldham KA; Bhatt RI; Lee SP; Searle PF
Cancer Immunol Immunother; 2012 May; 61(5):615-28. PubMed ID: 22021067
[TBL] [Abstract][Full Text] [Related]
11. Characterization of the Impact of Daclizumab Beta on Circulating Natural Killer Cells by Mass Cytometry.
Ranganath T; Simpson LJ; Ferreira AM; Seiler C; Vendrame E; Zhao N; Fontenot JD; Holmes S; Blish CA
Front Immunol; 2020; 11():714. PubMed ID: 32391016
[TBL] [Abstract][Full Text] [Related]
12. Lipopolysaccharide stimulates the proliferation of human CD56+CD3- NK cells: a regulatory role of monocytes and IL-10.
Goodier MR; Londei M
J Immunol; 2000 Jul; 165(1):139-47. PubMed ID: 10861046
[TBL] [Abstract][Full Text] [Related]
13. IL15 Infusion of Cancer Patients Expands the Subpopulation of Cytotoxic CD56
Dubois S; Conlon KC; Müller JR; Hsu-Albert J; Beltran N; Bryant BR; Waldmann TA
Cancer Immunol Res; 2017 Oct; 5(10):929-938. PubMed ID: 28842470
[TBL] [Abstract][Full Text] [Related]
14. CD56bright NK cells after hematopoietic stem cell transplantation are activated mature NK cells that expand in patients with low numbers of T cells.
Vukicevic M; Chalandon Y; Helg C; Matthes T; Dantin C; Huard B; Chizzolini C; Passweg J; Roosnek E
Eur J Immunol; 2010 Nov; 40(11):3246-54. PubMed ID: 20957748
[TBL] [Abstract][Full Text] [Related]
15. CD56bright NK cells are enriched at inflammatory sites and can engage with monocytes in a reciprocal program of activation.
Dalbeth N; Gundle R; Davies RJ; Lee YC; McMichael AJ; Callan MF
J Immunol; 2004 Nov; 173(10):6418-26. PubMed ID: 15528382
[TBL] [Abstract][Full Text] [Related]
16. CD56
Chen T; Liu C; Li L; Liu H; Wang T; Shao Z; Fu R
Int J Lab Hematol; 2019 Jun; 41(3):353-363. PubMed ID: 30779419
[TBL] [Abstract][Full Text] [Related]
17. Low baseline levels of NK cells may predict a positive response to ipilimumab in melanoma therapy.
Tietze JK; Angelova D; Heppt MV; Ruzicka T; Berking C
Exp Dermatol; 2017 Jul; 26(7):622-629. PubMed ID: 27892653
[TBL] [Abstract][Full Text] [Related]
18. CD56brightCD16- killer Ig-like receptor- NK cells display longer telomeres and acquire features of CD56dim NK cells upon activation.
Romagnani C; Juelke K; Falco M; Morandi B; D'Agostino A; Costa R; Ratto G; Forte G; Carrega P; Lui G; Conte R; Strowig T; Moretta A; Münz C; Thiel A; Moretta L; Ferlazzo G
J Immunol; 2007 Apr; 178(8):4947-55. PubMed ID: 17404276
[TBL] [Abstract][Full Text] [Related]
19. Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.
Nussenblatt RB; Thompson DJ; Li Z; Chan CC; Peterson JS; Robinson RR; Shames RS; Nagarajan S; Tang MT; Mailman M; Velez G; Roy C; Levy-Clarke GA; Suhler EB; Djalilian A; Sen HN; Al-Khatib S; Ursea R; Srivastava S; Bamji A; Mellow S; Sran P; Waldmann TA; Buggage RR
J Autoimmun; 2003 Nov; 21(3):283-93. PubMed ID: 14599854
[TBL] [Abstract][Full Text] [Related]
20. Invasive Surgery Impairs the Regulatory Function of Human CD56 bright Natural Killer Cells in Response to Staphylococcus aureus. Suppression of Interferon-γ Synthesis.
Reinhardt R; Pohlmann S; Kleinertz H; Hepner-Schefczyk M; Paul A; Flohé SB
PLoS One; 2015; 10(6):e0130155. PubMed ID: 26090673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
